Ellen Napier
YOU?
Author Swipe
View article: Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas
Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas Open
Background: CD19-directed CAR T-cell therapy (CAR-T) has improved outcomes and altered the treatment landscape for patients with relapsed/refractory large B-cell lymphomas (r/r LBCL). Despite these improvements, 60-70% of patients do not h…
Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas Open
The mechanisms underlying chimeric antigen receptor (CAR) T-cell failure are not fully understood; however, T-cell differentiation and presence of an immunosuppressive tumor microenvironment are thought to contribute. Ibrutinib, a Bruton t…
View article: Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas Open
Mosunetuzumab and other CD20/CD3 bispecific antibodies (BsAbs) have efficacy in B-cell lymphomas relapsing after or refractory to CD19-directed chimeric antigen receptor (CAR)–modified T cells (CAR-T). The optimal timing of BsAbs and bioma…
View article: Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia
Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia Open
Patients with B-cell lymphomas have altered cellular components of vaccine responses due to malignancy and therapy, and the optimal timing of vaccination relative to therapy remains unknown. Severe acute respiratory syndrome coronavirus 2 …
View article: Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines Open
Lymphodepletion (LD) is an integral component of chimeric antigen receptor T-cell (CART) immunotherapies. In this study, we compared the safety and efficacy of bendamustine (Benda) to standard fludarabine/cyclophosphamide (Flu/Cy) LD befor…
View article: Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL
Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL Open
Patients with B-cell lymphomas have altered cellular components of vaccine responses due to the malignancies and therapies. The optimal timing of vaccine administration relative to chemotherapy and immunotherapy remains unknown. The SARS-C…
View article: BENDAMUSTINE LYMPHODEPLETION TRIGGERS REDUCED INFLAMMATORY CYTOKINES AND DECREASED TOXICITIES AFTER BOTH 4‐1BB‐ AND CD28‐COSTIMULATED CART19 FOR NON‐HODGKIN LYMPHOMA
BENDAMUSTINE LYMPHODEPLETION TRIGGERS REDUCED INFLAMMATORY CYTOKINES AND DECREASED TOXICITIES AFTER BOTH 4‐1BB‐ AND CD28‐COSTIMULATED CART19 FOR NON‐HODGKIN LYMPHOMA Open
Introduction: Lymphodepletion (LD) is a key component of anti-CD19 chimeric antigen receptor T cell (CART19) immunotherapy, establishing the proper environment and cytokine milieu before CART infusion. We previously demonstrated that Benda…
Tisagenlecleucel Therapy: Nursing Considerations for the Outpatient Setting Open
This encompassing approach to patient management is particularly necessary during administration of tisagenlecleucel therapy and other CAR-T cell therapies that are managed in the outpatient setting.